Search results
Dosage and administration. Unless prescribed otherwise, take 1-2 sachets of Hepa-Merz ® 1-2 times daily. Dissolve the contents of the sachet in plenty of liquid (glass of water, tea or juice), and drink after meals. If required, the dosage may be increased without risk.
Hepa- Merz® Granules. Active substance: L-ornithine- L-aspartate. Indications: Treatment of concomitant disease and sequelae due to impaired detoxification activity (e.g. in cirrhosis of the liver) with the symptoms of latent and manifest hepatic encephalopathy. Contains orange yellow S (E110), fructose, aspartame.
Home – Hepa-Merz®: Professional Website
Hepa-Merz infusion concentrate is a clear solution. 4. CLINICAL PARTICULARS. 4.1 Therapeutic indications. Latent and manifest hepatic encephalopathy. 4.2 Posology and method of administration. Unless otherwise indicated, patients may be given up to 4 ampoules per day.
data are available relating to intake of Hepa-Merz® Granules in children and during pregnancy. No exhaustive animal studies have been performed for L-ornithine-L-aspartate, to investigate its toxicity in relation to reproduction. Administration of Hepa-Merz® Granules during pregnancy should therefore be avoided. If, however, treatment with Hepa-
CHARAKTERYSTYKA PRODUKTU LECZNICZEGO. 1. NAZWA PRODUKTU LECZNICZEGO. Hepa–Merz 3000, 3 g/5 g, granulat do sporządzania roztworu doustnego. 2. SKŁAD JAKOŚCIOWY I ILOŚCIOWY. Substancja czynna: L-ornityny L-asparaginian. 5 ggranulatu (1 saszetka) zawiera 3 g L-ornityny L-asparaginianu (Ornithini aspartas).
Podczas stosowania dużych dawek produktu Hepa-Merz należy kontrolować stężenie mocznika w surowicy i w moczu. W przypadku ciężkich zaburzeń czynności wątroby szybkość wlewu powinna być dostosowana indywidualnie, aby uniknąć zaburzeń żołądkowo-jelitowych, takich jak nudności lub wymioty. Dzieci
